Which has stronger earnings & valuation, AGMB or GNLX?

Genelux has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Genelux $10K 12,305.28 -$32.15M -$0.86 N/A

Is AGMB or GNLX more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Genelux N/A -205.85% -138.79%

Does the media favor AGMB or GNLX?

In the previous week, Genelux had 19 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 22 mentions for Genelux and 3 mentions for AgomAb Therapeutics. Genelux's average media sentiment score of 0.45 beat AgomAb Therapeutics' score of 0.25 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, PRTA or GNLX?

Genelux has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 51.11 -$244.09M -$0.84 N/A Genelux $10K 12,305.28 -$32.15M -$0.86 N/A

Is PRTA or GNLX more profitable?

Genelux has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -80.68% -16.45% -14.51% Genelux N/A -205.85% -138.79%

Does the media refer more to PRTA or GNLX?

In the previous week, Genelux had 17 more articles in the media than Prothena. MarketBeat recorded 22 mentions for Genelux and 5 mentions for Prothena. Prothena's average media sentiment score of 1.31 beat Genelux's score of 0.45 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, PROK or GNLX?

Genelux has lower revenue, but higher earnings than ProKidney. Genelux is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProKidney $890K 546.89 -$68.99M -$0.55 N/A Genelux $10K 12,305.28 -$32.15M -$0.86 N/A

Is PROK or GNLX more profitable?

Genelux has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets ProKidney -10,288.39% N/A -27.39% Genelux N/A -205.85% -138.79%

Does the media prefer PROK or GNLX?

In the previous week, Genelux had 13 more articles in the media than ProKidney. MarketBeat recorded 22 mentions for Genelux and 9 mentions for ProKidney. Genelux's average media sentiment score of 0.45 beat ProKidney's score of -0.38 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, RZLT or GNLX?

Genelux has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Genelux $10K 12,305.28 -$32.15M -$0.86 N/A

Is RZLT or GNLX more profitable?

Rezolute's return on equity of -58.82% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Genelux N/A -205.85% -138.79%

Does the media refer more to RZLT or GNLX?

In the previous week, Genelux had 20 more articles in the media than Rezolute. MarketBeat recorded 22 mentions for Genelux and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.39 beat Genelux's score of 0.45 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GNLX or EDIT more profitable?

Genelux has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. Editas Medicine's return on equity of -196.63% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -205.85% -138.79% Editas Medicine -157.32% -196.63% -38.17%

Does the media prefer GNLX or EDIT?

In the previous week, Genelux had 17 more articles in the media than Editas Medicine. MarketBeat recorded 22 mentions for Genelux and 5 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.64 beat Genelux's score of 0.45 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Genelux (GNLX) Competitors

$2.72 -0.02 (-0.73%)

As of 08/21/2026 04:00 PM Eastern

Compare

GNLX vs. AGMB, PRTA, PROK, RZLT, and EDIT

Should you buy Genelux stock or one of its competitors? Genelux's main competitors and comparable companies include AgomAb Therapeutics (AGMB), Prothena (PRTA), ProKidney (PROK), Rezolute (RZLT), and Editas Medicine (EDIT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genelux compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

AgomAb Therapeutics' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Genelux	N/A	-205.85%	-138.79%

In the previous week, Genelux had 19 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 22 mentions for Genelux and 3 mentions for AgomAb Therapeutics. Genelux's average media sentiment score of 0.45 beat AgomAb Therapeutics' score of 0.25 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genelux has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Genelux	$10K	12,305.28	-$32.15M	-$0.86	N/A

37.3% of Genelux shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AgomAb Therapeutics presently has a consensus price target of $33.00, suggesting a potential upside of 149.06%. Genelux has a consensus price target of $18.00, suggesting a potential upside of 561.76%. Given Genelux's higher possible upside, analysts plainly believe Genelux is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Genelux beats AgomAb Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Genelux compare to Prothena?

Prothena (NASDAQ:PRTA) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Prothena currently has a consensus target price of $23.75, indicating a potential upside of 151.32%. Genelux has a consensus target price of $18.00, indicating a potential upside of 561.76%. Given Genelux's higher possible upside, analysts plainly believe Genelux is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Prothena has a beta of -0.3, suggesting that its share price is 130% less volatile than the broader market. Comparatively, Genelux has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Genelux has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	51.11	-$244.09M	-$0.84	N/A
Genelux	$10K	12,305.28	-$32.15M	-$0.86	N/A

Genelux has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Genelux	N/A	-205.85%	-138.79%

In the previous week, Genelux had 17 more articles in the media than Prothena. MarketBeat recorded 22 mentions for Genelux and 5 mentions for Prothena. Prothena's average media sentiment score of 1.31 beat Genelux's score of 0.45 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.1% of Prothena shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Prothena beats Genelux on 10 of the 17 factors compared between the two stocks.

How does Genelux compare to ProKidney?

ProKidney (NASDAQ:PROK) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

51.6% of ProKidney shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ProKidney presently has a consensus target price of $12.00, suggesting a potential upside of 645.34%. Genelux has a consensus target price of $18.00, suggesting a potential upside of 561.76%. Given ProKidney's stronger consensus rating and higher possible upside, research analysts plainly believe ProKidney is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Genelux has lower revenue, but higher earnings than ProKidney. Genelux is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	546.89	-$68.99M	-$0.55	N/A
Genelux	$10K	12,305.28	-$32.15M	-$0.86	N/A

ProKidney has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Genelux has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Genelux has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Genelux	N/A	-205.85%	-138.79%

In the previous week, Genelux had 13 more articles in the media than ProKidney. MarketBeat recorded 22 mentions for Genelux and 9 mentions for ProKidney. Genelux's average media sentiment score of 0.45 beat ProKidney's score of -0.38 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats Genelux on 11 of the 17 factors compared between the two stocks.

How does Genelux compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Rezolute presently has a consensus price target of $9.38, indicating a potential upside of 84.18%. Genelux has a consensus price target of $18.00, indicating a potential upside of 561.76%. Given Genelux's higher probable upside, analysts clearly believe Genelux is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Rezolute has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Genelux has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

In the previous week, Genelux had 20 more articles in the media than Rezolute. MarketBeat recorded 22 mentions for Genelux and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.39 beat Genelux's score of 0.45 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rezolute's return on equity of -58.82% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Genelux	N/A	-205.85%	-138.79%

Genelux has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Genelux	$10K	12,305.28	-$32.15M	-$0.86	N/A

83.0% of Rezolute shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Rezolute beats Genelux on 8 of the 14 factors compared between the two stocks.

How does Genelux compare to Editas Medicine?

Genelux (NASDAQ:GNLX) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

37.3% of Genelux shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Genelux had 17 more articles in the media than Editas Medicine. MarketBeat recorded 22 mentions for Genelux and 5 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.64 beat Genelux's score of 0.45 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genelux has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. Editas Medicine's return on equity of -196.63% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Editas Medicine	-157.32%	-196.63%	-38.17%

Genelux has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	12,305.28	-$32.15M	-$0.86	N/A
Editas Medicine	$40.52M	11.79	-$160.06M	-$0.75	N/A

Genelux has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

Genelux currently has a consensus price target of $18.00, indicating a potential upside of 561.76%. Editas Medicine has a consensus price target of $5.50, indicating a potential upside of 76.85%. Given Genelux's higher possible upside, equities research analysts plainly believe Genelux is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Editas Medicine beats Genelux on 9 of the 16 factors compared between the two stocks.

Get Genelux News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNLX vs. The Competition

Export

Metric	Genelux	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$123.07M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-3.16	11.62	272.60	24.24
Price / Sales	12,305.28	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	7.56	16.80	13.05	6.20
Net Income	-$32.15M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-0.73%	3.29%	2.09%	0.08%
1 Month Performance	-8.11%	8.23%	6.64%	3.88%
1 Year Performance	-28.04%	55.05%	25.02%	16.98%

Genelux Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNLX Genelux	2.2188 of 5 stars	$2.72 -0.7%	$18.00 +561.8%	-28.0%	$123.07M	$10K	N/A	10	News Coverage Analyst Forecast Analyst Revision
AGMB AgomAb Therapeutics	2.7654 of 5 stars	$13.47 +0.3%	$33.00 +145.0%	N/A	$488.15M	N/A	N/A	62	News Coverage Analyst Forecast
PRTA Prothena	3.4174 of 5 stars	$9.30 +3.0%	$23.75 +155.4%	+7.8%	$486.86M	$9.68M	N/A	130	Insider Trade
PROK ProKidney	1.9761 of 5 stars	$1.59 +11.6%	$12.00 +657.1%	-33.2%	$479.18M	$890K	N/A	3	News Coverage Insider Trade
RZLT Rezolute	2.9889 of 5 stars	$4.95 +6.2%	$9.38 +89.4%	-27.3%	$476.65M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNLX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genelux (GNLX) Competitors

GNLX vs. AGMB, PRTA, PROK, RZLT, and EDIT

How does Genelux compare to AgomAb Therapeutics?

Summary

How does Genelux compare to Prothena?

Summary

How does Genelux compare to ProKidney?

Summary

How does Genelux compare to Rezolute?

Summary

How does Genelux compare to Editas Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genelux (GNLX) Competitors

GNLX vs. AGMB, PRTA, PROK, RZLT, and EDIT

How does Genelux compare to AgomAb Therapeutics?

Is AGMB or GNLX more profitable?

Does the media favor AGMB or GNLX?

Which has stronger earnings & valuation, AGMB or GNLX?

Do insiders & institutionals have more ownership in AGMB or GNLX?

Do analysts prefer AGMB or GNLX?

Summary

How does Genelux compare to Prothena?

Do analysts prefer PRTA or GNLX?

Which has more volatility and risk, PRTA or GNLX?

Which has higher earnings & valuation, PRTA or GNLX?

Is PRTA or GNLX more profitable?

Does the media refer more to PRTA or GNLX?

Do insiders and institutionals believe in PRTA or GNLX?

Summary

How does Genelux compare to ProKidney?

Do insiders & institutionals have more ownership in PROK or GNLX?

Do analysts prefer PROK or GNLX?

Which has preferable earnings & valuation, PROK or GNLX?

Which has more risk and volatility, PROK or GNLX?

Is PROK or GNLX more profitable?

Does the media prefer PROK or GNLX?

Summary

How does Genelux compare to Rezolute?

Do analysts rate RZLT or GNLX?

Which has more risk and volatility, RZLT or GNLX?

Does the media refer more to RZLT or GNLX?

Is RZLT or GNLX more profitable?

Which has better valuation and earnings, RZLT or GNLX?

Do institutionals and insiders have more ownership in RZLT or GNLX?

Summary

How does Genelux compare to Editas Medicine?

Do institutionals & insiders believe in GNLX or EDIT?

Does the media prefer GNLX or EDIT?

Is GNLX or EDIT more profitable?

Which has stronger valuation & earnings, GNLX or EDIT?

Which has more risk and volatility, GNLX or EDIT?

Do analysts recommend GNLX or EDIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools